MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration to evaluate multiple agents from Erasca’s pipeline targeting the RAS/MAPK pathway as either single-agent or combination therapies.
The initial focus of the alliance will be Erasca’s potentially best-in-class ERK1/2 inhibitor ERAS-007 and its potentially best-in-class SHP2 inhibitor ERAS-601,...
Allison Institute announces formation of scientific advisory board
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its scientific advisory...
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive...
MD Anderson and Empyrean announce agreement to develop novel radiation therapy technologies
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development agreement to advance novel technologies and products in the fields of radiation oncology and cancer therapeutics.
This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to...
MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode...